Dr. Yeku’s research involves characterizing the suppressive tumor microenvironment and evaluating strategies to improve the efficacy of novel immunotherapeutic approaches for the management of gynecologic malignancies. This includes immune checkpoint inhibitors, antibody-drug conjugates, bispecific T-cell engager therapy, and adoptive cellular therapy, including CAR-T cells. His research involves the use of relevant cell lines, preclinical animal models, and clinical trials. Dr. Yeku has published on the role of the immunosuppressive tumor microenvironment in ovarian cancer, in addition to devising cell engineering approaches to overcoming this challenge. His research builds on his expertise as a physician scientist focusing exclusively on Gynecologic Medical Oncology. He sees patients in clinic, performs translational research, and runs clinical trials ranging from phase 1 to randomized phase 3 studies. His affiliation with the MGH phase 1/Developmental therapeutics clinic and the cellular therapeutics group allows him a platform to translate his laboratory findings to clinical trials.